Janus Henderson Group PLC Uni Qure N.V. Transaction History

Janus Henderson Group PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$18.7 - $23.07 $395,037 - $487,353	21,125 New	21,125 $425,000
Q1 2021 May 17, 2021	SELL	$29.24 - $42.03 $20.6 Million - $29.6 Million	-704,838 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$35.35 - $50.67 $103,822 - $148,817	2,937 Added 0.42%	704,838 $25.5 Million
Q3 2020 Nov 16, 2020	SELL	$35.98 - $47.66 $1.2 Million - $1.59 Million	-33,428 Reduced 4.55%	701,901 $25.9 Million
Q2 2020 Aug 14, 2020	BUY	$45.06 - $67.74 $378,413 - $568,880	8,398 Added 1.16%	735,329 $33.1 Million
Q1 2020 May 14, 2020	BUY	$40.01 - $73.97 $29.1 Million - $53.8 Million	726,931 New	726,931 $34.5 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.